All News
Extension PEXIVAS study in ANCA vasculitis pts with severe DAH
- no significant effect of PLEX on mortality but do note numerical difference, favoring PLEX in severe DAH
- note difference in curve
@RheumNow #RNL2023 https://t.co/6ktb3Uakw9
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilars back on the radar for 2023. Expect to see 17 in rheum. #RNL2023 @RheumNow https://t.co/SNYNM8nmD2
Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilar to biosimilar switching of Infliximab , @RheumNow Kavanaugh #RNL2023
Communications is a key always.
Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Will be begin using sputum instead of blood serologies to detect RA?
- sputum seropositive CCP may be associated with development of clinical RA
- 4 fold higher risk if (induced) sputum CCP+
@RheumNow #RNL2023 https://t.co/Z85GDwIyl8
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
Sputum antibody predicts future development of RA
Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA)
Strongest association with CCP IgA
Supports pre-RA as mucosal disease
@RheumNow https://t.co/Js4JPZiLDB
Eric Dein ericdeinmd ( View Tweet)
How does HCQ work
@Lupusreference in #RNL2023
HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN
HCQ works as base to increase lysosomal pH and affect cellular function
@RheumNow https://t.co/RTEUF0cS0u
Eric Dein ericdeinmd ( View Tweet)
@Lupusreference in #RNL2023
HCQ and arrhythmia via QTc prolongation
At normal doses, same as general population
If on other QTc prolonging medications, a baseline EKG may be beneficial
@RheumNow https://t.co/cAN2vBNa1t
Eric Dein ericdeinmd ( View Tweet)
Any dose more than 1500 is associated with retinopathy ? So what to do. @Lupusreference #RNL2023 @RheumNow https://t.co/2zdjpcuvKa
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Smoking and SLE
Smoking increases SLE activity
Smoking decreases HCQ efficacy
Skin response on HCQ down 50% in smokers 🚬
@Lupusreference #RNL2023 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
TULIP trials in lupus, disease outcomes and others, by Richard Furie #RNL2023 @RheumNow https://t.co/uUQOxUIzJN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Furie: #RNL2023
Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease
Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature
@RheumNow https://t.co/30oFRwwuTG
Eric Dein ericdeinmd ( View Tweet)
✅ Check my TAKE-HOME MESSAGES about #hydroxychloroquine & #Lupus for RheumNow Live 2023 #RNL2023
@RheumNow ⬇️ https://t.co/E2xdv3ODG6
Laurent ARNAUD Lupusreference ( View Tweet)
SRI Responders more likely able to reduce prednisone and far
Serological improvement
SF-36
Fatigue
by Richard Furie #RNL2023 @RheumNow https://t.co/ilsyOXw7nA
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Compliance is always an issue, by Richard Furie #RNL2023 @RheumNow .
Plaquenil level were below target. Adherence is always something we need to work on. https://t.co/hMgL9kY0rZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Ken Kalunian on Lupus nephritis
Don't forget about ACEi/ARB therapy for SLE pts with renal involvement
- can control BP
- reduce Urine proteinuria
- decrease risk of active renal disease
#RNL2023 @RheumNow https://t.co/hLBqjELqW2
Robert B Chao, MD doctorRBC ( View Tweet)
UPCR< 500 mg is the best predictor of a renal outcome in lupus nephritis. Multiple creatinine testing, Ken Kalunian #RNL2023 @RheumNow https://t.co/96PlXgqOfK
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Belimumab in Active lupus nephritis , Ken Kalunian #RNL2023 @RheumNow https://t.co/VZkmK8Iny7
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Carpal Tunnel - Steroid injection vs. Night Splinting
A randomized trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSIor NS as the initial treatment of CTS.
https://t.co/dcE2P6RqoC https://t.co/pykkXs8qqi
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of adverse outcomes in PsA pregnancies
More pre eclampsia
More Cesarian section
More preterms
By Dr.Chambers #RNL2023 @RheumNow https://t.co/LRiSSpv4Yj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)